EI
OREX

EAM Investors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

EAM Investors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,994
Closed -$1.33M – 440
2015
Q1 		$1.33M Buy
+16,994
New +$1.05M 0.15% 254
2013
Q4 		– Sell
-15,667
Closed -$962K – 426
2013
Q3 		$962K Sell
15,667
-1,391
-8% -$94.2K 0.19% 283
2013
Q2 		$998K Buy
+17,058
New +$1.05M 0.22% 239

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

EAM Investors's OREX Position: Q2 2015 in Review

EAM Investors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 16,994 shares — an estimated $1.33M sold.

EAM Investors first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $1.33M in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • EAM Investors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • EAM Investors sold 16,994 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $1.33M.
  • EAM Investors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • EAM Investors's Orexigen Therapeutics, Inc. position peaked at $1.33M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on EAM Investors's 13F filing for Q2 2015, filed 13 Aug 2015.